EXHIBIT 99.1

AETHLON MEDICAL, INC.

FOR IMMEDIATE RELEASE: Contact:
Anne Hoversten
Aethlon Medical, Inc.
Investor Relations
858.459.7800 x300
anne@aethlonmedical.com



AETHLON MEDICAL APPOINTS JAMES W. DORST
AS CHIEF FINANCIAL OFFICER


San Diego, CA, August 2, 2005 - Aethlon Medical, Inc. (OTCBB:AEMD) announced
today that James W. Dorst has been appointed Chief Financial Officer. Mr. Dorst
brings close to 20 years of senior management experience in finance, operations,
planning and business transactions to the Company. Prior to joining Aethlon, Mr.
Dorst was Vice President of Finance and Operations for VerdiSoft Corporation, a
developmental-stage mobile-software developer recently acquired by YAHOO, INC.
(NASDAQ: YHOO). Previously, Mr. Dorst held executive positions as SVP of Finance
and Administration at SeeCommerce; COO/CFO of Omnis Technology Corp (now NASDAQ
Small Cap: RDTA); CFO and SVP of Information Technology at Savoir Technology
Group, Inc. (acquired by NYSE:AVT). Mr. Dorst practiced as a Certified Public
Accountant with Coopers & Lybrand (PricewaterhouseCoopers) and holds an MS in
Accounting and BS in finance from the University of Oregon.

"The Aethlon family is excited to have an executive of Jim's caliber and
experience joining our team as a full-time CFO," stated Chairman and CEO, James
A. Joyce, "He will play a critical role in the effort to transition our science
from the labs and into the marketplace." Joyce added, "I also want to take this
opportunity to thank Ned Hall for his contribution to our success thus far and
wish him well in future endeavors". Mr. Hall, a principal with Tatum partners,
has acted as CFO since August of 2002.

About Aethlon Medical

Aethlon Medical is pioneering the development of viral filtration devices to
treat drug and vaccine resistant pathogens. The market focus is the treatment of
the Human Immunodeficiency Virus (HIV), Hepatitis-C (HCV), and Biological Weapon
Threats. Aethlon has an experienced management team, which receives support and
guidance from globally recognized science advisors representing the infectious
disease, biowarfare, and dialysis industries. Clinical Trials to treat HIV and
HCV patients in India are scheduled to begin in the coming months, and U.S.
clinical studies are expected to begin later this year. More information on
Aethlon Medical and the Hemopurifier technology is available at
www.aethlonmedical.com.


CERTAIN OF THE STATEMENTS HEREIN MAY BE FORWARD-LOOKING AND INVOLVE RISKS AND
UNCERTAINTIES. SUCH FORWARD-LOOKING STATEMENTS INVOLVE ASSUMPTIONS, KNOWN AND
UNKNOWN RISKS, UNCERTAINTIES AND OTHER FACTORS WHICH MAY CAUSE THE ACTUAL
RESULTS, PERFORMANCE OR ACHIEVEMENTS OF AETHLON MEDICAL, INC TO BE MATERIALLY
DIFFERENT FROM ANY FUTURE RESULTS, PERFORMANCE, OR ACHIEVEMENTS EXPRESSED OR
IMPLIED BY THE FORWARD-LOOKING STATEMENTS. SUCH POTENTIAL RISKS AND
UNCERTAINTIES INCLUDE, WITHOUT LIMITATION, THE COMPANY'S ABILITY TO RAISE
CAPITAL WHEN NEEDED, THE COMPANY'S ABILITY TO COMPLETE THE DEVELOPMENT OF ITS
PLANNED PRODUCTS, THE ABILITY OF THE COMPANY TO OBTAIN FDA AND OTHER REGULATORY
APPROVALS PERMITTING THE SALE OF ITS PRODUCTS, THE COMPANY'S ABILITY TO
MANUFACTURE ITS PRODUCTS AND PROVIDE ITS SERVICES, THE IMPACT OF GOVERNMENT
REGULATIONS, PATENT PROTECTION ON THE COMPANY'S PROPRIETARY TECHNOLOGY, PRODUCT
LIABILITY EXPOSURE, UNCERTAINTY OF MARKET ACCEPTANCE, COMPETITION, TECHNOLOGICAL
CHANGE, AND OTHER RISK FACTORS. IN SUCH INSTANCES, ACTUAL RESULTS COULD DIFFER
MATERIALLY AS A RESULT OF A VARIETY OF FACTORS, INCLUDING THE RISKS ASSOCIATED
WITH THE EFFECT OF CHANGING ECONOMIC CONDITIONS AND OTHER RISK FACTORS DETAILED
IN THE COMPANY'S SECURITIES AND EXCHANGE COMMISSION FILINGS.